Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

AGM Statement

22 Oct 2012 07:00

RNS Number : 1601P
ABCAM Plc
22 October 2012
 



For immediate release 22 October 2012

 

 

ABCAM PLC

("Abcam" or "the Company")

 

AGM Statement

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, is this morning holding its Annual General Meeting.

Michael Redmond, Abcam's Chairman, will make the following statement:

"Last month, in our preliminary results, we highlighted the challenges faced in our Western markets as Governments address fiscal deficits, including the effect of uncertainty about future levels of research funding on researchers' spending. These challenges remain a feature of our markets, particularly in the US ahead of the election later this year.

"Despite this backdrop, the Board believes that Abcam is well positioned to deliver continued growth. The integration of the Epitomics reagents business is proceeding successfully and the Board is pleased with the Company's profitability in the first three months of the financial year."

 

For further information please contact:

 

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

Numis Securities - Nominated Advisor and Joint Broker

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Advisor

James Black - Corporate Broking

Peel Hunt LLP - Joint Broker

+ 44 (0) 207 418 8900

Andy Crossley - Corporate Broking

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 600 staff across its eight operating companies.

Abcam now has an online catalogue of over 98,000 products sourced from more than 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website, www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMBKDDNKBDBOKB
Date   Source Headline
2nd Jul 20089:10 amRNSShareholding
7th May 20083:31 pmRNSGrant of Share Options
1st May 20087:01 amRNSTrading Update
29th Apr 20085:08 pmRNSShareholding
2nd Apr 20087:01 amRNSDirector's Dealings
26th Mar 200812:08 pmRNSShareholding
20th Mar 20083:35 pmRNSTransfer of Shares
17th Mar 200812:08 pmRNSShareholding
14th Mar 200812:02 pmRNSDirectors' Dealings
10th Mar 20087:02 amRNSInterim Results
15th Feb 20083:33 pmRNSShareholding
13th Feb 20087:00 amRNSShareholding
12th Feb 20087:00 amRNSNotification of Results
10th Dec 200712:55 pmRNSShareholding
7th Dec 20078:00 amRNSAnnual Report and Accounts
6th Dec 20079:29 amRNSDirector's Dealings
4th Dec 20074:14 pmRNSBlocklisting
28th Nov 20074:58 pmRNSShareholding
27th Nov 20077:01 amRNSShareholding
23rd Nov 20072:44 pmRNSShareholding
23rd Nov 20077:01 amRNSAdditional Listing
12th Nov 20077:01 amRNSLaboratory Collaboration
8th Nov 20074:18 pmRNSResult of AGM
7th Nov 20077:01 amRNSCFO Appointment
25th Oct 20077:01 amRNSShareholding
24th Oct 200712:17 pmRNSShareholding
23rd Oct 20074:37 pmRNSShareholding
23rd Oct 20073:50 pmRNSAdditional Listing
19th Oct 200711:21 amRNSExercise of Share Options
18th Oct 200712:21 pmRNSDirectors' Dealings
17th Oct 200712:38 pmRNSShareholding
16th Oct 20077:01 amRNSSecures Further Antibodies
11th Oct 200712:31 pmRNSShareholding
11th Oct 200712:30 pmRNSShareholding
1st Oct 20077:02 amRNSPreliminary Results
24th Sep 200711:06 amRNSNotice of Results
20th Sep 200710:08 amRNSEPT Disclosure
19th Sep 20077:02 amRNSRe Offer Discussions
17th Sep 20079:53 amRNSEPT Disclosure
13th Sep 200711:57 amRNSRule 8.3- Abcam
13th Sep 20079:59 amRNSEPT Disclosure
12th Sep 200711:58 amRNSRule 8.3- Abcam
11th Sep 20079:38 amRNSEPT Disclosure
10th Sep 200710:19 amRNSEPT Disclosure
31st Aug 20072:28 pmPRNRule 8.3 - Abcam plc
31st Aug 200712:02 pmRNSRule 8.3- Abcam
31st Aug 200710:27 amRNSEPT Disclosure
31st Aug 200710:08 amRNSRule 8.3-Abcam Plc
30th Aug 200712:24 pmRNSRule 8.3- Abcam plc
30th Aug 20079:43 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.